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Diabetes mellitus is a metabolic disease with multiple complications that causes serious diseases over the years. The
condition leads to severe economic consequences and is reaching pandemic level globally. Much research is being
carried out to address this disease and its underlying molecular mechanism. This review focuses on the diverse role
and mechanism of ceramide, a prime sphingolipid signaling molecule, in the pathogenesis of type 1 and type 2
diabetes and its complications. Studies using cultured cells, animal models, and human subjects demonstrate that
ceramide is a key player in the induction of β-cell apoptosis, insulin resistance, and reduction of insulin gene
expression. Ceramide induces β-cell apoptosis by multiple mechanisms namely; activation of extrinsic apoptotic
pathway, increasing cytochrome c release, free radical generation, induction of endoplasmic reticulum stress and
inhibition of Akt. Ceramide also modulates many of the insulin signaling intermediates such as insulin receptor
substrate, Akt, Glut-4, and it causes insulin resistance. Ceramide reduces the synthesis of insulin hormone by
attenuation of insulin gene expression. Better understanding of this area will increase our understanding of the
contribution of ceramide to the pathogenesis of diabetes, and further help in identifying potential therapeutic
targets for the management of diabetes mellitus and its complications.
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Diabetes mellitus is one of the leading causes of death
worldwide, ranking amongst cardiovascular diseases and
cancer. Diabetes may be classified into two groups based
on its pathophysiology. One is caused by autoimmune
destruction of β-cells (Type 1 or Insulin dependent dia-
betes), while the other is due to the progressive decline
of pancreatic β-cell function in the context of insulin re-
sistance (Type 2 or Non-insulin dependent diabetes) [1].
The major morbidity threats of diabetes are often micro-
vascular (retinopathy, nephropathy and neuropathy) and
macrovascular (cardiovascular diseases) complications
[1,2]. According to a recent World Health Organization
report, 3.2 million deaths worldwide are attributable to
diabetes every year [2]. The number of people with dia-
betes will be more than double over the next 20 years,
reaching a total of 366 million by 2030 [2]. Therefore, a* Correspondence: sehamuddin@uaeu.ac.ae
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reproduction in any medium, provided the orbetter understanding of the disease and its pathophysio-
logical mechanism is of paramount importance.
Sphingolipids, one of the major classes of lipid within
the mammalian lipidome, are characterized by the pres-
ence of sphingoid base in their structure [3]. They are
ubiquitous constituents of eukaryotic membranes that
play a key role in the regulation of signal transduction
pathways [4,5]. Deregulation of sphingolipids is impli-
cated in numerous diseases including cancer [6], cardio-
vascular diseases [7], and neurodenerative disorders [8].
Over the past two decades, accumulating evidence has
shown a clear indication that sphingolipids such as cer-
amide, sphingosine and glycosphingolipids (GSL), have
important role in the pathogenesis of both type 1 and 2
diabetes and its associated complications.
The aim of this review is to shed light on the current
understanding of the role and mechanism of ceramide in
diabetes, and to highlight areas requiring further study.
Understanding the complex mechanism of ceramide ac-
tion in diabetes requires adequate knowledge of insulin
signal transduction and sphingolipid biosynthesis.
Therefore, the first two sections of this review providel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bolic pathways. This review also summarizes the role,
and potential cellular signaling mechanisms of ceramide
in β-cell apoptosis, insulin resistance, and attenuation of
insulin gene expression. This review will also very briefly
discuss the role of ceramide in some of the diabetic
complications.
Insulin signaling pathway
Insulin, an endocrine hormone produced from the pan-
creatic β-cells, plays a key role in glucose homeostasis
[9,10]. Insulin action is mediated through insulin recep-
tor (IR) that propagates its activity via three different
pathways: phosphatidylinositol-3 kinase (PI3K) pathway,
mitogen-activated protein kinase (MAPK) pathway, and
Cbl-associated protein (CAP) pathway [11,12]. The PI3K
pathway is the major pathway involved in glucose trans-
port, and is significantly distorted by ceramide. The
present review specifically focuses on this particular
pathway of glucose regulation.
Insulin receptor is a tyrosine kinase receptor which


















Figure 1 Major pathways in insulin receptor signaling and mechanism
abbreviations are described in the text. Briefly, activation of insulin recepto
level by inducing glucose uptake, glycogen synthesis, protein synthesis and
of the metabolic effects of insulin may also be mediated via other signaling
PP2A and PKCζ mediated inhibition of Akt and MLK-3 mediated inhibition
Cer, Ceramide.brane β-subunits [11]. Upon insulin binding to the α-
subunit, IR undergoes autophosphorylation of tyrosine
residues in the intracellular β-domain. Insulin receptor
substrate (IRS) has a phosphotyrosine binding domain
that recognizes the activated IR, and in turn leads to
tyrosine phosphorylation and activation of IRS (Figure 1)
[11]. Once activated, IRS allows the binding and activa-
tion of PI3K which phosphorylates the membrane lipid
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phos-
phatidylinositol (3,4,5)-triphosphate (PIP3). Protein kin-
ase B (PKB, also known as Akt) is recruited to the
plasma membrane and activated at PIP3 site in the pres-
ence of phosphoinositide-dependant protein kinase-1
(PDK1) [10]. The activation of Akt allows its
relocalization to the cytosol, where it causes the trans-
location of the glucose transporter-4 (Glut-4) to the
plasma membrane, thereby promoting glucose uptake
(Figure 1) [13]. Akt also phosphorylates and inactivates
glycogen synthase kinase-3 (GSK3), an enzyme involved
in glycogen synthase phosphorylation and inactivation.
This results in an increase in glucose storage as glycogen












of ceramide in insulin resistance. Details of these processes and
r leads to Akt activation. Once activated, Akt reduce blood glucose
fatty acid synthesis. Akt also act by inhibiting gluconeogenesis. Some
branches than those depicted. Ceramide causes insulin resistance by
of IRS. Ceramide may also decrease Glut-4 gene transcription.
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an essential participant in the initiation of protein trans-
lation. Hence, the inactivation of GSK3 by Akt promotes
protein synthesis making the amino acids less available
for gluconeogenesis [12]. Akt also excludes transcription
factor Forkhead box O1 (FOXO1) from the nucleus,
abolishing FOXO1 mediated expression of
gluconeogenic enzymes such as glucose-6-phosphatase
(G6P), fructose-1,6-biphosphatase (F16BP) and phospho-
enolpyruvate carboxykinase (PEPCK) (Figure 1) [12,14].
Akt activates mammalian target of rapamycin (mTOR)
which promotes protein synthesis through activation of
p70 ribosomal S6 kinase (p70S6K), and the inhibition of
eIF4E binding protein (eIF4EBP) [15,16]. The activation
of mTOR by Akt also promotes fatty acid (FA) uptake
and synthesis by activating transcription factor sterol
regulatory binding protein 1C (SREBP-1c) which is a
protein that enhances the transcription of FA and trigly-
ceride biosynthetic enzymes (Figure 1) [12,14].
Sphingolipid biosynthesis: regulation and
compartmentalization
The biosynthetic pathway of sphingolipids consists of a
complex network of synthetic and degradative reactions.Ceram


























Figure 2 Regulation of sphingolipid biosynthesis. Details of these proc
formed from L-serine and palmitoyl CoA via de novo pathway. Ceramide c
hydrolysis by Glucocerebrosidase and from sphingosine by ceramide synth
shown outside the box. Some pharmacological inhibitors of sphingolipid bThe de novo biosynthesis of sphingolipids occurs at the
cytosolic leaflet of the endoplasmic reticulum (ER). Dur-
ing this, 3-ketosphinganine is formed by the condensa-
tion of L-serine and palmitoyl CoA by the action of an
enzyme serine palmitoyl transferase (SPT). The newly
formed 3-ketosphinganine first undergoes rapid reduc-
tion to dihydrosphingosine by the action of 3-
ketosphinganine reductase, which is then acetylated to
form dihydroceramide (dh-Cer) by the action of dh-Cer
synthase. The enzyme dh-Cer desaturase reduces dh-Cer
to ceramide (Figure 2) [4,5,17]. Ceramide serves as a
‘metabolic hub’ in the sphingolipid metabolic pathway as
a substrate for subsequent production of other sphingo-
lipid signaling intermediates [18-20]. Neutral ceramidase
in the ER, alkaline ceramidase in the plasma membrane,
and acid ceramidase in the lysosome may hydrolyze cer-
amide to generate sphingosine. Sphingosine may be
phosphorylated to sphingosine-1-phosphate (S1P) by
sphingosine kinase. The formation of sphingosine from
ceramide and S1P from sphingosine can be reversed by
enzymes ceramide synthase and S1P phosphatase re-
spectively (Figure 2).
Ceramide once formed in ER, is transported to the
























esses and abbreviations are described in the text. Briefly, ceramide is
an also be formed from SM hydrolysis by SMase, glucosyl ceramide
ase. Sphingolipid metabolites are depicted in box and enzymes are
iosynthetic enzymes are also shown.
Galadari et al. Lipids in Health and Disease 2013, 12:98 Page 4 of 16
http://www.lipidworld.com/content/12/1/98Golgi is the site for the synthesis of sphingomyelin (SM)
and glucosylceramide, with the latter serving as the precur-
sor for complex GSLs. An enzyme SM synthase-1 at Golgi,
and SM synthase-2 at plasma membrane transfer a
phosphorylcholine head group to ceramide and form SM
with the release of diacylglycerol (DAG) [4,20]. Alkaline and
neutral sphingomyelinase (SMase) at the plasma membrane,
and acid SMase at the lysosome can reverse this reaction
to generate ceramide back from SM. Glucosylceramide is
formed from ceramide by action of membrane bound
glucosylceramide synthase (GCS), which can be further
converted to complex GSLs by different sialyl transferases.
In the lysosome, complex GSLs are degraded back to
glucosylceramide, and then to ceramide by the enzymes gly-
cosidases and glucocerebrosidase, respectively [20]. In an al-
ternative pathway, ceramide is phosphorylated at the plasma
membrane by ceramide kinase. Its product, ceramide-1
-phosphate (C1P), can be hydrolyzed back by C1P phosphat-
ase to generate ceramide (Figure 2) [21].
Ceramide in pancreatic beta-cell apoptosis
Role of ceramide in beta-cell apoptosis
Apoptosis is a programmed death of cells that plays an
important role in the maintenance of tissue homeostasis
by eliminating harmful or unwanted cells. The mechan-
ism of apoptosis involves complex signaling pathways.
The three currently recognized apoptotic signaling path-
ways are: the extrinsic death receptor, the intrinsic mito-
chondrial, and the intrinsic ER pathways [22,23].
Literature suggests that the excessive apoptosis of pan-
creatic β-cell contributes significantly in the pathogen-
esis of both type 1 [24] and type 2 [25] diabetes. The
role of ceramide in β-cell apoptosis in both type 1 and
type 2 diabetes is also well established.
Cytokines such as tumor necrosis factor-alpha (TNF-
α), Interleukin-1 beta (IL-1β) and Interferon-gamma
(IFN-γ) are known to exert cytotoxic effects on pancre-
atic β-cells [26]. Emerging evidence suggest that cer-
amide has a role in β-cell apoptosis induced by these
cytokines [27]. Exposure of insulin-producing MIN6
cells and RINm5F cells to TNF-α and IL-1β, respectively,
results in an increase in ceramide production. In
addition, ceramide, either delivered exogenously or gen-
erated endogenously, mimicked the cytotoxic effect of
TNF-α and IL-1β in these cell lines [28-30]. On the
other hand, another β-cell model, β-TC3 cells did not
show an increase in ceramide when treated with cyto-
kines [31]. This disparity may be due to an immediate
activation of ceramidase in β-TC3 cells as reported with
INS-1 β-cells [32]. Ceramidase is capable of converting
the ceramide to sphingosine which can be further
converted to S1P by sphingosine kinase. This is further
evidenced with the presence of enhanced S1P level in
INS-1 cells following treatment with IL-1β and TNF-α[33]. Such a possibility has to be tested in β-TC3 cells
employing sensitive assay methods.
Long-standing evidence implicates that prolonged ex-
posure to free fatty acid (FFA) has detrimental effects on
pancreatic β-cells. Ceramide has been proposed to be a
mediator of FFA-induced β-cell toxicity. Palmitate, a
precursor of ceramide has been found to induce islet cell
apoptosis in diabetic rat models, healthy rats, and human
β-cells [34-36]. However, unsaturated FA failed to induce
this effect [35,37,38]. Similarly, studies conducted in Zucker
diabetic fatty (ZDF) rats demonstrated that ceramide
formed via the de novo pathway is responsible for the FFA-
induced β-cell apoptosis. This is evidenced with the appear-
ance of marked increase in [3H]-ceramide up on culturing
islet cells in the presence of either [3H]-serine or [3H]-
palmitate [34,39]. In addition, inhibition of ceramide
synthesis using SPT inhibitor (L-cycloserine) or ceramide
synthase inhibitor (fumonisin-B1), has been reported to at-
tenuate FFA-induced cytotoxicity in both rodent [34,35,39]
and human [37,40] β-cells. In contrast, some studies with
β-cell apoptosis have reported only modest increase in cer-
amide upon treatment with FFA. However, inhibition of de
novo ceramide synthesis reduced the apoptosis significantly
[41]. There could be three possible explanations for this
contradictory result. First, an increase in ceramide at par-
ticular cellular location, without altering the total ceramide
mass may be sufficient to induce apoptosis. This is sup-
ported by the fact that ceramide synthesized in the ER can
be transported to other organelles including mitochondria,
and moreover, mitochondria itself contains the enzymatic
machinery necessary for ceramide synthesis [42]. A second
possible explanation is conversion of ceramide to another
sphingolipid metabolite after apoptotic induction. To sup-
port this, Boslem et al. identified an increase in glucosyl
ceramide, a metabolite of ceramide up on treatment of
MIN β-cells with FFA. They also found that the
overexpression of glucosyl ceramide synthase, an enzyme
that converts ceramide to glucosyl ceramide, did not ex-
acerbate, but partially protected from apoptosis [43]. Fi-
nally, apoptotic potential of ceramide may vary with
different isoforms. Veret et al. demonstrated that FFA, at
low glucose concentration, increased all ceramide species,
but at elevated glucose concentration increased the more
toxic C18:0, C22:0 and C24:1 isoforms of ceramide specific-
ally to enhance apoptosis [44]. Conclusive data from these
studies demonstrate that ceramide generated via the de
novo pathway is the key player in the execution of FFA-
induced β-cell apoptosis.
Mechanism of ceramide induced beta-cell apoptosis
Activation of extrinsic apoptotic pathway It has been
generally accepted over the past few decades that activa-
tion of the extrinsic pathway of apoptosis plays a
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gins outside the cell with the binding of death ligands,
such as TNF-α and Fas ligand, to their respective cell-
surface death receptors such as TNF receptor and Fas
(CD95). This binding of the receptor by its cognate lig-
and results in the recruitment and activation of initiator
caspase (mostly caspase-8), which then propagates apop-
tosis by cleaving and activating downstream effector
caspases such as caspase-3 [45,46]. Agent that induces
ceramide accumulation en route to β-cell apoptosis,
such as cytokines and saturated FAs, were also reported
to activate the extrinsic pathway of apoptosis [27,35]
(Figure 3). Normal pancreatic β-cells exhibit only min-
imal expression of Fas, but when exposed to cytokines,
such as IL-1, an increase in Fas expression was observed
[47]. Pancreatic β-cell that lacks caspase-8 has shown
protection against both Fas and ceramide-induced cell
death, suggesting the role of ceramide in it [48]. More-
over, Liadis et al. demonstrated that caspase-3 knockout
mice protected from developing diabetes [49], signifying
the role of caspase cascade in β-cell apoptosis.
Alteration of mitochondrial membrane permeation
Ceramide induces β-cell apoptosis by increasing the
mitochondrial membrane permeability, leading to the
activation of the intrinsic pathway of apoptosis. The in-









Figure 3 Schematic representation of mechanism of beta-cell apopto
are described in the text. Briefly, cellular ceramide can be formed by de no
extrinsic pathway of apoptosis by FasL or TNF-α binding to the Fas and TN
causes the release of ROS/RNS and cytochrome c and activates intrinsic ap
generation. Ceramide can act on the ER and cause ER stress mediated apoin response to a wide range of death stimuli. Regardless
of the stimuli, pro-apoptotic molecule, such as cyto-
chrome c, is released into the cytosol which together
with another pro-apoptotic protein, Apoptotic protease
activating factor 1 (Apaf-1) activates the initiator caspase
(mostly caspase-9). The initiator caspase then activates
an effector caspase such as caspase-3 that propagates
the apoptotic signal [50]. The intrinsic pathway is regu-
lated by a group of proteins belonging to the B-cell
lymphoma-2 (Bcl-2) family. There are two main groups
of the Bcl-2 proteins, namely the pro-apoptotic proteins
(e.g. Bad, Bid, Bax, Bak, Bcl-Xs, Bim, etc) and the anti-
apoptotic proteins (e.g. Bcl-2, Bcl-xL, Mcl-1, etc). The
anti-apoptotic proteins reduce apoptosis by blocking the
mitochondrial release of cytochrome-c, while the pro-
apoptotic proteins act by promoting it. The fate of the
cell is determined by the tilt in their ratio towards one
or the other [46,50].
Ceramide either delivered exogenously or generated
endogenously when targeted to the mitochondria, an in-
crease in its permeability to cytochrome c and apoptosis
is observed [51,52] (Figure 3). The apoptotic action of
ceramide is mediated by the recruitment and activation
of pro-apoptotic Bax at the mitochondria. Birbes et al.
[53] and Kashkar et al. [54], demonstrated that induction
of SMase, an enzyme that converts SM to ceramide, pro-
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chrome c [55]. In agreement with this, depleting the Bax
or antagonizing its activity by overexpressing Bcl-2,
prevented ceramide-induced apoptosis [56,57]. The in-
trinsic mitochondrial pathway is also involved in the
FFA-induced β-cell apoptosis. It has been reported that
exposure of β-cells to saturated FAs results in enhanced
mitochondrial membrane permeability and cytochrome
c release [58]. Furthermore, reduction in Bcl-2 expres-
sion [36] and Bax up-regulation [58] was also observed
when β-cells were exposed to FFAs. Jointly, these studies
suggest that ceramide generated from FFA may very well
be involved in the activation of the intrinsic apoptosis
pathway. Yet, another mechanism of ceramide in mito-
chondrial membrane alteration has also been proposed.
Siskind et al. proposed that ceramide is directly capable
of forming channels in the mitochondrial membrane,
thus, increasing its permeability to cytochrome c [59].
This action of ceramide has not been extensively studied
yet. Ceramide also interferes with Akt activation, and
thereby, promotes the mitochondrial membrane perme-
ability, and cytochrome c release by preventing the Akt-
induced inactivation of pro-apoptotic Bcl-2 members
[60].
Free radical generation Reactive oxygen species (ROS)
and reactive nitrogen species (RNS) are some of the key
integrating mediators in the development of β-cell apop-
tosis. Although, relevant amount of ROS and RNS are
essential for maintaining normal physiological signaling
and metabolic functions, excessive amount of these radi-
cals can lead to cell death and tissue damage [61]. Cer-
amide plays an important role in ROS and RNS
generation through activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase [62], initiation
of mitochondrial dysfunction [63], induction of inducible
nitric oxide synthase (iNOS) gene expression [64], and
down-regulation of anti-apoptotic Bcl-2 proteins [65].
Conversely, a growing body of evidence also suggests
that ROS and RNS enhance ceramide generation by
inducing SMase [66], or inhibiting ceramidase [67] en-
zymes (Figure 3). Although, these effects are not exten-
sively studied in the pancreatic β-cells, the bidirectional
interaction of ceramide and ROS/RNS may also be in-
volved in the apoptotic cascades in β-cells.
The major source of ROS in most cells is the leakage
of electrons from complex I and complex III of the
mitochondrial respiratory chain [14]. Inhibition or re-
duction of activities of these complexes results in elec-
tron leakage, and elevated ROS level which in turn can
lead to β-cell apoptosis. Ceramide has been shown to
disrupt electron transport at complex I [68] and com-
plex III [69], resulting in an enhanced ROS generation
which facilitates cytochrome c release and caspaseactivation [63]. Similarly, TNF-α, a known inducer of
ceramide is also found to inhibit complex III activity
[14]. As described earlier, activation of NADPH oxidase
by ceramide also leads to ROS generation and apoptosis
if it is not rapidly removed by the antioxidant defense
[62]. The exact mechanism of ceramide-mediated
NADPH oxidase activation is not known, but it is be-
lieved that ceramide activates protein kinase C zeta
(PKCζ), which facilitates binding of p67phox, a catalytic
subunit of NADPH oxidase, to its holo enzyme complex
[70,71]. Another mechanism of ceramide-induced free
radical generation is via regulation of anti-apoptotic Bcl-
2 protein. Bcl-2 prevents ROS production, increases
antioxidant GSH pool and redistributes it [65]. In islet
cells, ceramide is reported to decrease Bcl-2 mRNA
expression [72]. Yet, another mechanism of ceramide-
induced free radical generation is via increased expres-
sion of iNOS, which codes for iNOS enzyme involved in
the synthesis of nitric oxide (NO) in response to inflam-
matory stimuli such as cytokines and lipotoxicity. Cer-
amide, either generated via the de novo pathway [73] or
SM hydrolysis [74], is reported to induce nuclear factor
kappa B (NFκB), a transcription factor involved in the
expression of iNOS gene activation. When islets of ZDF
rats were supplied with FAs, an increase in apoptosis
along with increased iNOS expression and nitric oxide
formation was observed [34]. These effects were blocked
by fumonisin B1 and aminoguanidine, a NOS inhibitor
[34], suggesting the role of ceramide in it. Finally, ROS
also acts by inducing ER stress that further induces β-
cell apoptosis [75]. In conclusion, all these studies sug-
gest that ROS/RNS generation triggered by ceramide
may be one of the crucial factors in promoting apoptosis
in many mammalian cells and animal models, but fur-
ther studies are required to understand the complete in-
volvement of these free radicals in β-cell apoptosis.
Induction of ER stress Accumulating evidence suggests
that ER stress plays an important role in β-cell apoptosis
[76,77]. During diabetes there will be high secretory de-
mand for insulin placed on the pancreatic β-cells to
counteract hyperglycemia. The ER, being the site of syn-
thesis and folding of secreted proteins, is highly suscep-
tible to stress when the demand for insulin folding and
secretion exceeds its capacity [78,79]. This increased ER
stress leads to accumulation of misfolded and unfolded
insulin in the ER, which may activate Unfolded Protein
Response (UPR) to restore the normal ER function.
When restoration fails, UPR switches in to an alternative
mode and turns on the apoptotic signaling pathway in
the β-cells. Oyadomari et al. and Socha et al. demon-
strated ER stress-induced β-cell apoptosis in diabetic
animal models [80,81]. Similarly, elevated levels of ER
stress markers were observed in islets of diabetic human
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been shown to promote ER stress to induce β-cell apop-
tosis [82,83]. This specific toxic effect of saturated FAs
may be related to the formation of ceramide from it
[41]. Collectively, observations from several studies dem-
onstrate that ceramide synthesis via the de novo pathway
is involved in ER stress-induced β cell apoptosis [43,44].
In line with this, ceramide generated via SM hydrolysis
has also been reported to cause ER stress-induced β-cell
apoptosis. Lei et al demonstrated that activation of Ca2
+ -independent phospholipase A2 (iPLA2β), an inducer
of β-cell apoptosis in response to strong ER stress, pro-
motes ceramide accumulation secondary to the activa-
tion of neutral SMase, an enzyme that hydrolyzes SM to
generate ceramide [84]. Inhibition of neutral SMase
protected β-cell from ER stress induced apoptosis, dem-
onstrating the importance of ceramide in ER stress-
induced cell death. Ceramide generated by ER stress also
activates intrinsic mitochondrial pathway of apoptosis in
β-cells by altering the mitochondrial membrane perme-
ability and release of cytochrome c [84]. ER stress and
induction of UPR can also result in ROS generation, and
the role of ROS, both as upstream and downstream, to
ceramide activation is well known [85].
Inhibition of Akt A major mechanism through which
ceramide induces β-cell apoptosis is by its inhibitory ac-
tion on Akt, a serine/threonine kinase which regulates
several biological processes including cellular growth,
proliferation and survival in multiple organs (Figure 3).
Akt mediates its proliferative and anti-apoptotic action
on the pancreatic β-cell through several mechanisms.
First, Akt phosphorylates and induces cytosolic retention
of cyclin-dependent kinase inhibitors (CKI) such as
p21Cip1 and p27Kip1. This enhances the proteosomal
degradation of these CKIs [86]. Second, Akt negatively
regulates the transcriptional activity of FOXO1, which is
known to upregulate p27kip1 [86]. Third, Akt directly
phosphorylates and inactivates pro-apoptotic Bcl-2
members such as Bad, Bax and Bid [87]. Finally, Akt ac-
tivates mTOR/p70S6K mediated cell growth and prolif-
eration [15,16]. Through all these mechanisms, Akt
promotes the cell cycle, proliferation and inhibition of
apoptosis.
An inverse correlation between ceramide and Akt acti-
vation has been reported in cultured cells when exposed
to ceramide [12,15,16,88-90]. Akt inactivation along with
ceramide accumulation is also observed in rats treated
with glucocorticoids and saturated fat [91]. Inhibition of
ceramide biosynthesis using myriocin, cycloserine, or
fumonisin B1 restored the Akt activity [15,91,92]. As an
alternative strategy to manipulate endogenous ceramide,
cultured cells when treated with PDMP, an inhibitor of
ceramide glucosylation, exacerbated palmitate-inducedAkt inactivation [93]. This palmitate effect was reversed
by over expressing acid ceramidase [92,94]. These stud-
ies support the hypothesis that Akt inactivation by cer-
amide is one of the contributing mechanisms by which
ceramide causes β-cell apoptosis. The mechanism
through which ceramide inhibits Akt activity will be
discussed later in this review.
Ceramide in insulin resistance
Role of ceramide in insulin signaling and action
It is becoming increasing apparent that ceramide plays
significant role in insulin resistance, a metabolic state in
which cells fail to respond to the normal hormonal ac-
tions of insulin. Evidence from various studies revealed
that excess FFA intake, glucocorticoid administration,
obesity, and lack of physical exercise are some of the im-
portant causations leading to insulin resistance. Plethora
of studies using wide variety of cultured cells, animal
models and human subjects demonstrated ceramide as
the key intermediate linking all these conditions to insu-
lin resistance [95].
Preliminary evidence underpinning the role of cer-
amide in insulin resistance came from the direct applica-
tion of ceramide to isolated skeletal muscles and
cultured adipocytes. These studies indicate that ceramide
inhibits insulin-stimulated glucose uptake and glycogen
synthesis [96,97]. Increased delivery of saturated FA in
excess of a tissue’s oxidative or storage capacity is one of
the main reasons for insulin resistance. Prolonged ex-
posure of palmitate to cultured myotubes [15], L6 skel-
etal muscle cells [16], 3 T3-L1 adipocytes [98] and
cardiac myocytes [99] increases ceramide accumulation
with simultaneous inhibition of Akt. Consistent with
this, palmitate exposure also caused a reduction in glu-
cose uptake and glycogen synthesis [92]. Subsequent
studies using pharmacological inhibitors or small inter-
fering RNA (siRNA) to block the enzymes involved in
ceramide biosynthesis, have demonstrated that ceramide
is an obligate intermediate in saturated FA-induced insu-
lin resistance [94,100,101]. In agreement with this,
overexpression of acid ceramidase as an alternative
approach to reduce the ceramide level, negated the
palmitate-induced ceramide accumulation and improved
insulin signaling [93]. Similarly, acute application of cer-
amide analogue to 3 T3-adipocytes mimicked the palmi-
tate induced insulin desensitizing effect [102].
As mentioned earlier, some groups also studied the
role of saturated FA in insulin resistance using animal
models, including high fat-fed mice, ob/ob mice, lipid-
infused rats, dexamethasone-treated rats and ZDF rats
[103-105]. Recently, Frangioudakis et al. demonstrated
that mice fed with high-fat diet shows increased expres-
sion of ceramide synthase [103]. Infusion of lipid emul-
sion in animal model has shown to increase muscle
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tivity [105]. These effects were blocked by using SPT in-
hibitors, indicating the role of ceramide [105]. Recently,
Holland et al. compared the effect of lard oil (high in
saturated FAs) and soy oil (high in unsaturated FAs) on
insulin sensitivity in rats. They found that both of these
treatments decreased glucose uptake and Akt activation,
but ceramide increase was observed only with lard-oil
infusion [105]. Similarly, several other studies also could
not find considerable increase in ceramide in response
to lipid supplementation, but an elevated DAG level was
observed [106,107]. When carefully examined, some of
these studies were found to use lipid rich in unsaturated
FA, indicating that saturated fats and unsaturated fats
have different mechanisms of promoting insulin resist-
ance, and ceramide plays a role only in insulin resistance
induced by saturated fats [105]. As mentioned earlier,
the experiments conducted to study the effect of FA on
ceramide generation and insulin resistance, were not
only restricted to cell lines and animal models. Studies
conducted in human subjects also provided precious in-
formation. Studies conducted using insulin-resistant hu-
man subjects demonstrated almost two fold increase in
ceramide accumulation compared to normal subjects
[108]. In another study, lipid infusion in humans is
found to increase skeletal muscle ceramide and decrease
insulin sensitivity [109].
Apart from inducing ceramide generation, chronic ex-
posure to elevated concentrations of FAs have been
reported to modulate several other effectors and signal-
ing pathways, to induce beta-cell dysfunction and apop-
tosis. Some of those effectors include endocannabinoids,
eicosanoids, cytokines, and transcription factors.
Endocannabinoids are FA derivatives implicated in
the regulation of energy balance, hepatic lipogenesis,
and glucose homeostasis [110,111]. Elevated levels of
endocannabinoids, such as 2-arachidonoylglycerol or
anandamide, have been implicated in hyperglycemia
and decreased insulin sensitivity in high fat fed mice
and obese human subjects [111]. Inhibition of
endocannabinoid activity, using endocannabinoid recep-
tor antagonist, resulted in increased glucose uptake in
diabetic mice models [111]. Eicosanoids are another
class of FA derivatives that play vital role in the control
of pancreatic β-cell function and survival [112,113]. Cy-
clooxygenase derived eicosanoids, such as prostaglandin
E2 and eicosanoids of 12-Lipoxygenases, have been
found to attenuate glucose-stimulated insulin secretion
and increase beta-cell destruction in the pancreas [113].
NF-κB is a transcription factor which is best known for
its immune and inflammatory responses. Key role of the
NF-kB pathway in the induction of inflammatory re-
sponses, that underlie type 2 diabetes, has been
highlighted in several studies [114,115]. Fatty acids, inparticular saturated FAs induce the expression of NF-κB
through Toll-like receptor 4 (TLR4) signaling [115]. An
improvement in insulin sensitivity was observed in ani-
mal model of FFA-induced insulin resistance when the
gene encoding for TLR4 was mutated [115].
Glucocorticoids are most commonly used therapeutic
agents, although contraindicated in diabetes as they can
cause insulin resistance [116]. Previously, it has been
demonstrated that glucocorticoids induce ceramide gen-
eration which may be responsible for its induction of in-
sulin resistance [105]. Dexamethasone, a widely used
glucocorticoid was shown to increase ceramide level in
broad range of cell types, and animal subjects through
stimulation of enzymes such as SPT, SMase and cer-
amide synthase [105,117,118]. Some of this effect was
completely prevented by pre-treating the subjects with
myriocin [105]. It has been reported that glucocorticoid-
induced ceramide accumulation and associated insulin
resistance requires activation of peroxisome proliferator
activated receptor (PPAR) alpha. As an evidence to this,
genetic ablation of PPAR alpha, or disruption of hepatic
vagal nerves (which decreases hepatic PPAR alpha expres-
sion) prevented dexamethasone-induced insulin resistance
[119,120]. Thiazolidinediones (TZDs) are most commonly
used anti-diabetic agent which functions as insulin sensi-
tizers [121]. It is found that TZDs like pioglitazone [122],
troglitazone [123], and rosiglitazone [124] decrease cer-
amide accumulation in muscles of rat or mice. Fenretinide,
a chemotherapeutic agent is found to improve insulin sen-
sitivity in high fat-fed mice, was recently identified as an
inhibitor of dihydroceramide desaturase. Thus, insulin-
sensitizing actions of some of these drugs may result from
its inhibitory effects on ceramide synthesis [125].
Physical exercise is widely perceived to be beneficial
for glycemic control in type 2 diabetes, as it improves in-
sulin sensitivity and glucose homeostasis [126]. Routine
exercise training is found to decrease ceramide content
in skeletal muscles of rat, mice [127,128] and human
subjects [129,130]. In contrast, some studies could not
report significant decrease in muscle ceramide level even
after exercise training in rats and humans [131,132]. The
reason for this discrepancy remains unclear. Obesity and
associated increase in pro-inflammatory cytokines is an-
other key player of insulin resistance [133]. Patients with
obesity have elevated level of the inflammatory cytokine
such as TNF-α [134]. The role of TNF-α in ceramide
generation has already been discussed in this review. Fi-
nally, insulin resistance increases with age. Wu et al.
demonstrated that adipocytes from older mice contained
higher ceramide compared to younger one [135]. Con-
clusive evidence from all these studies suggests that in-
hibitors of ceramide synthesis or activators of ceramide
degradation may prove efficacious as therapeutics to
combat insulin resistance.
Galadari et al. Lipids in Health and Disease 2013, 12:98 Page 9 of 16
http://www.lipidworld.com/content/12/1/98Mechanism of ceramide-induced insulin resistance
The precise molecular mechanisms by which changes in
ceramide might cause insulin resistance are not entirely
clear. Although, it seems likely that ceramide influences
several distinct intermediates in the insulin signaling
pathway. Some of these potential mechanisms by which
ceramide may impair insulin signaling and action are
discussed below.
Ceramide on IRS Kanety et al. reported that ceramide
inhibits insulin stimulated tyrosine phosphorylation of
IRS-1 [136]. This is confirmed by some other studies
which demonstrated that ceramide phosphorylates in-
hibitory serine residues on IRS-1 [136,137]. The prob-
able mechanism is that ceramide activates mixed lineage
kinase-3 [138] (Figure 1), which in turn activates stress-
activated protein kinases such as p38 and c-Jun N-
terminal kinase (JNK) [139,140]. These enzymes have
been implicated in phosphorylation of serine-307 on
IRS-1 [141,142]. This in turn inhibits the necessary tyro-
sine phosphorylation needed for insulin signal transduc-
tion [143]. In agreement to this, Hirosumi et al.
demonstrated an increase in JNK activity and serine-307
phosphorylation, and a decrease in tyrosine phosphoryl-
ation of IRS-1 in tissues of obese mice [142]. In another
study, mutations in the gene coding for JNK-binding
protein (an inhibitor of JNK activity) in humans caused
type 2 diabetes [10,144]. Even though these studies dem-
onstrated ceramide-induced inhibition of IRS-1, other
studies did not find any correlation [16,92].
Ceramide on PI3K, PDK1, Phosphoinositides (PIP2
and PIP3) and Glut-4 Several studies evaluated the role
of sphingolipids on PI3K [16,91,92], PDK1 [145],
phosphoinositide (PIP2 and PIP3) [146,147] and Glut-4
[98]. However, majority of these studies failed to see any
direct effect. Although Zundel et al. reported that cer-
amide inhibits PI3K activity [148], yet, its relevance in
the regulation of glucose homeostasis remains unclear.
Ceramide on Akt/PKB The role of ceramide in regulat-
ing the Akt to induce β-cell apoptosis has been
discussed in the preceding section of this review. Indeed,
the involvement of Akt in β-cell physiology might go be-
yond the induction of apoptosis and include the regula-
tion of insulin secretion. Therefore, the inhibition of Akt
by ceramide might have a negative impact on insulin
sensitivity as well by abrogating all Akt mediated insulin
activities (Figure 1).
Inhibition of Akt activation by ceramide is thought
to be accomplished by at least two mechanisms. First,
ceramide activates protein phosphatase 2A [92,149]
(Figure 3) which catalyses the dephosphorylation of Akt
by removing activating phosphates [92,145,146,150]. TheAkt inhibitory effect of ceramide in cell lines like PC12
cells [145], C2C12 myotubes [92], human glioblastoma
cell [150], and brown adipocytes [149], was negated by
the PP2A inhibitor, Okadaic acid. When PP2A activity
was impaired by over expressing SV40 small T antigen
(which displaces the regulatory subunits that target
PP2A to its substrates), the effect of ceramide on Akt
was blocked [99]. Second, ceramide blocks insulin-
stimulated Akt translocation to the PIP3-PDK1 complex
at the plasma membrane [16,147]. Powell et al. and
Bourbon et al demonstrated that ceramide binds to cyst-
eine rich ceramide binding domain on PKCζ and acti-
vates it [94,151,152] (Figure 3). The activated PKCζ in
turn phosphorylates inhibitory the serine or threonine
residue (depending on the Akt isoforms) at the site 34 in
the pleckstrin homology (PH) domain of Akt [152]. This
prevents its interactions with PIP3, may be by forming
more stable Akt-PKCζ complex [94,152]. In agreement
with this mechanism, PKCζ inhibitors were found to in-
crease insulin sensitivity and prevent ceramide-induced
loss of Akt activation [152,153].
Ceramide in lipid raft and diabetes
Lipid rafts are specialized micro-domains of plasma
membrane that contain high concentrations of lipid de-
rived molecules such as cholesterol, sphingolipids and a
subset of phospholipids [154]. Sphingomyelin is the
most prevalent sphingolipid present in the outer leaflet
of the plasma membrane and hence in the lipid raft. The
SM within the raft can be hydrolyzed by SMase and lead
to the generation of ceramide [155] (Figure 4). Previ-
ously discussed key players of diabetes induction such as
TNF receptor activation, Fas activation and ROS gener-
ation were reported to activate SMase and hence gener-
ate ceramide in the rafts [156]. Ceramide molecules
associate with each other and immediately form small
ceramide-enriched membrane microdomains. The gen-
eration of ceramide and its tight packing within rafts
dramatically alters the structure and composition of
these domains. This results in spatial re-organization
and clustering of several cytokine and death receptors,
including Fas and TNF receptors [155,156]. This recep-
tor clustering perhaps could promote β-cell apoptosis
through proximity induced caspase activation (Figure 4).
In line with this, cells that lack SMase activity failed to
release ceramide and induce apoptosis upon Fas and
TNF receptor stimulation [157]. Consistent with this,
neutralization of ceramide in ceramide-enriched mem-
brane domains using anti-ceramide antibodies inhibited
Fas-induced apoptosis [158]. However, additional experi-
mental evidence is required to elucidate the entire role
of receptor clustering in diabetes.
Caveolae are a subset of lipid rafts seen as flask like in-
























Figure 4 Schematic representation of role of ceramide in lipid raft and diabetes. Details of the processes and abbreviations are described
in the text. Briefly, the SM within the raft can be hydrolyzed by SMase to form ceramide which immediately self-associate and form ceramide
enriched membrane domains. This raft coalescence facilitates apoptosis by initiating proximity induced caspase activation. Ceramide recruits both
PKCζ and Akt to the caveolae. By doing so, ceramide can not only activate PKCζ, but also causes co-localization of activated PKCζ with Akt, there
by suppressing Akt activity. Ceramide also recruits PTEN in the caveolae which dephosphorylate PIP3 and impair insulin signaling. Cer, Ceramide.
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ence of proteins termed caveolin, a family of scaffolding
proteins which play significant role in numerous signal-
ing pathways by compartmentalizing and concentrating
signaling molecules [159]. Generally, optimal level of
caveolae is important for the proper insulin signaling.
However, excessive caveolae is reported to impair insulin
signaling and action, basically via two mechanisms. First,
ceramide extensively recruits and elevates phosphatase
and tensin homolog deleted on chromosome 10 (PTEN)
in caveolae. The anti-proliferative PTEN specifically ca-
talyses the dephosporylation of the 3′ phosphate in PIP3
and convert it to PIP2 (Figure 4). This decrease in PIP3
in turn, impairs insulin signaling because it is essential
for the activation of Akt in response to the IR activation
by insulin [160,161]. Second, ceramide recruits both
PKCζ and Akt to the caveolae which will have synergetic
repressive effect on insulin signaling. Briefly, recruitment
of both PKCζ and Akt by ceramide leads to the collect-
ive presence of ceramide, PKCζ and Akt in the caveolae
[153,161] (Figure 4). By doing so, PKCζ would not only
be exposed to ceramide rendering it active, but at the
same time would be co-localized with Akt, there by sup-
pressing its activity. Both of these mechanisms together
create a highly repressive environment for Akt, and
hence, diminish insulin mediated signaling response.
Ceramide and insulin synthesis
Thus far, we have mainly considered the role for cer-
amide in inducing β-cell apoptosis and insulin resist-
ance. However, several studies reveal that ceramide also
diminishes insulin synthesis by decreasing the insulin
mRNA levels in islets. In pancreatic β cells, saturated FA
has been shown to impair insulin gene expression with
associated increase in ceramide [162,163]. This effect
was largely prevented by inhibitors of de novo ceramidesynthesis suggesting the role for ceramide [163]. Further-
more, addition of exogenous ceramide or elevation of
endogenous ceramide, using ceramidase inhibitor, has
been demonstrated to reduce insulin mRNA levels
[163,164]. Two postulations have been made to explain
the mechanisms of inhibition of insulin gene transcrip-
tion by ceramide. First, ceramide activates JNK which in-
hibits insulin gene transcription both via c-jun
-dependent [165], and oxidative stress-dependent [166]
pathways. Second, ceramide directly activates PKCζ
[167] which phosphorylates and inactivates Pancreatic
and duodenal homeobox gene-1 (PDX-1), a transcription
factor which regulates insulin gene expression [168].
Apart from down-regulating insulin gene transcription,
ceramide has also been shown to decrease transcription
of the Glut-4 gene [169] (Figure 1). In conclusion, these
results suggest that ceramide modulates signaling path-
ways implicated in the transcriptional regulation of the
insulin gene. However, further investigation is required
to understand the exact mechanism of inhibition of in-
sulin gene expression by ceramide.
Ceramide in diabetic complications
The major threats of diabetes are its serious, sometimes
life-threatening complications. A growing body of
evidence has identified the role of sphingolipids, particu-
larly ceramide, in the pathogenesis of both micro-
vascular and macrovascular diabetic complications.
Cardiovascular diseases such as atherosclerosis, myocar-
dial infarction and stroke, are major cause of mortality
in diabetic patients. Diabetic cardiomyopathy is charac-
terized by the apoptosis of cardiomyocytes [170]. In-
creased myocardial ceramide content was observed in
various rodent models of lipotoxic cardiomyopathy
[171,172]. De novo ceramide biosynthesis, when
inhibited either pharmacologically by myriocin, or
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improvement in the cardiac function was observed
[171,172]. Apart from this, Gorska et al. demonstrated
an elevated acid SMase level in plasma of type 2 diabetic
patients [173]. Ceramide has also been implicated in ath-
erosclerosis in both human subjects and in animal
models [174,175], and regression of atherosclerotic
plaques was observed when treated with myriocin [176].
Conclusively, these studies suggest that ceramide gener-
ated via de novo pathway and SM hydrolysis may be in-
volved in the development of diabetic cardiovascular
complications.
Nephropathy represents another major threat in dia-
betic patients which is characterized by the apoptosis of
renal mesangial cells. Several studies reported the role of
ceramide in mesangial cell apoptosis. Increased expres-
sion of SPT was seen in renal tubular epithelial and
microvascular endothelial cells, which are the main sites
of apoptosis observed in diabetic patients [177]. When
ceramide generation was inhibited using SPT inhibitors
and ceramide synthase inhibitors, a reduction in tubular
epithelial cell death was observed [178,179]. Another im-
portant complication associated with diabetes is devel-
opment of neuropathy. Except for the gangliosides, role
of sphingolipids in diabetic neuropathy is not extensively
studied. When mouse Schwann cells were cultured with
palmitate, an enhancement in apoptosis was observed.
This effect was significantly suppressed by myriocin and
fumonisin B1, suggesting a role for ceramide [180]. An-
other important complication of diabetes is retinopathy,
the second leading cause of blindness in the developed
countries [181]. When cultured retinal pericytes were in-
cubated with palmitate, an increase in cellular ceramide
content with subsequent increase in apoptosis was ob-
served [182]. This effect was reversed by overexpression
of ceramidase [182]. In another study where ceramide
accumulation was induced by using Advanced Glycation
End products, Fumonisin B1 did not reverse the retinal
pericyte apoptosis, suggesting that de novo biosynthesis
is not involved in the ceramide generation [183]. Here,
desipramine, an acid SMase inhibitor, almost completely
abolished ceramide generation and apoptosis, demon-
strating that ceramide is formed from SM hydrolysis
[183].
These observations underline the potential involve-
ment of ceramide in the pathogenesis of diabetic compli-
cations. Moreover, some of the studies also
demonstrated the role of other sphingolipids such as
GSL in diabetic nephropathy [184] and retinopathy
[185]. However, whether it is ceramide or GSL that play
a more important role in these diabetic complications is
not known. Further research employing more advanced
lipidomic screening will definitely bring the answer to
this question.Conclusion
There has been considerable progress over the last few
years in unraveling the role and mechanism of ceramide
action in diabetes and its complications. Taken together,
evidence from a plethora of studies indicates that cer-
amide plays a significant role in diabetes by at least three
different mechanisms: inducing pancreatic β-cell apop-
tosis, increasing insulin resistance, and reducing insulin
gene expression. Translated to the clinical level, all of
these ceramide mediated pathways remain candidates
for their putative contributions to the pathogenesis of
diabetes. However, there are still several unanswered
questions. First, it is not known what enables ceramide
to mediate so many diverse signaling events in the cell.
Though different species of ceramide exist, the role and
critical importance of each species in the pathophysi-
ology of diabetes is not as yet completely known. May
be this species diversity is responsible for the multiple
cellular events mediated by ceramide. Secondly, Cer-
amide generated in the ER can be transported to differ-
ent organelles, and moreover, many organelles contain
the machinery that enables them to synthesize ceramide.
Hence, the quantitative and qualitative aspects of cer-
amide in different sub-cellular compartments must be
extensively studied. Third, sphingolipids have highly
interconnected metabolic networks, so alteration of cer-
amide might have deleterious impact on other sphingo-
lipid metabolites. The impact of such modifications on
the normal functioning of cells must be studied. Finally,
the factors that regulate sphingolipid biosynthetic en-
zymes to generate ceramide during diabetes induction
have to be investigated extensively. Further elucidation
of these molecular details will be essential to develop
better understanding of the validity of ceramide modula-
tion as a strategy for treating diabetes. Advances in ana-
lytical lipidomics such as tandem mass spectrometry and
lipid imaging could provide more crucial information re-
garding the role of ceramide in the etiology and patho-
genesis of diabetes in the coming years. Such an
understanding undoubtedly will have a direct impact on
future therapies for diabetes.
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